Live price temporarily unavailable.
Biodesix (BDSX) is a Health Care company. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $24.6M | $45.6M | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Growth (year over year) | — | +85.6% | +19.6% | −29.9% | +28.5% | +45.3% | +24.1% |
| Operating income | −$26.7M | −$22.9M | −$40.9M | −$50.6M | −$41.3M | −$34.5M | −$27.9M |
| Operating margin | −108.9% | −50.3% | −75.1% | −132.4% | −84.2% | −48.4% | −31.5% |
| Net income | −$30.7M | −$65.4M | −$43.2M | −$65.4M | −$52.1M | −$42.9M | −$35.3M |
| Net margin | −125.1% | −143.7% | −79.2% | −171.3% | −106.2% | −60.2% | −39.8% |
| EPS (diluted) | −$50788.00 | −$2592.00 | −$31.60 | −$31.00 | −$12.80 | −$6.64 | −$4.67 |
| Balance sheet | |||||||
| Cash and equivalents | $5.29M | $62.1M | $32.7M | $43.1M | $26.3M | $26.2M | $19.0M |
| Total assets | $45.0M | $121.1M | $76.1M | $92.9M | $99.1M | $97.2M | $87.5M |
| Total liabilities | $76.2M | $79.9M | $56.4M | $72.3M | $94.5M | $76.4M | $89.9M |
| Long-term debt | — | $28.1M | $10.1M | $30.1M | $40.1M | $40.0M | $50.0M |
| Shareholders' equity | −$225.1M | $41.2M | $19.7M | $20.6M | $4.58M | $20.9M | −$2.46M |
| Cash flow | |||||||
| Operating cash flow | −$21.7M | −$21.4M | −$28.2M | −$45.0M | −$22.9M | −$48.6M | −$23.3M |
| Capital expenditure | $1.31M | $1.95M | $2.24M | $3.30M | $22.9M | $3.23M | $259.0K |
| Free cash flow | −$23.0M | −$23.3M | −$30.5M | −$48.3M | −$45.8M | −$51.9M | −$23.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.2M | $20.4M | $18.0M | $20.0M | $21.8M | $28.8M | $25.6M | $26.9M |
| Growth (year over year) | +34.5% | +39.3% | +21.2% | +11.7% | +19.9% | +40.8% | +42.3% | +34.2% |
| Operating income | −$8.59M | −$6.65M | −$9.14M | −$9.72M | −$7.05M | −$1.97M | −$6.20M | −$5.39M |
| Operating margin | −47.3% | −32.5% | −50.9% | −48.6% | −32.4% | −6.8% | −24.3% | −20.1% |
| Net income | −$10.3M | −$8.25M | −$11.1M | −$11.5M | −$8.72M | −$3.98M | −$7.79M | −$7.27M |
| Net margin | −56.5% | −40.4% | −61.8% | −57.3% | −40.0% | −13.8% | −30.5% | −27.1% |
| EPS (diluted) | −$1.40 | −$0.84 | −$1.52 | −$1.56 | −$1.16 | −$0.43 | −$0.81 | −$0.71 |
| Balance sheet | ||||||||
| Cash and equivalents | $31.4M | $26.2M | $17.6M | $20.7M | $16.6M | $19.0M | $25.6M | $30.0M |
| Total assets | $102.7M | $97.2M | $86.2M | $87.7M | $88.7M | $87.5M | $94.6M | $95.3M |
| Total liabilities | $74.9M | $76.4M | $75.2M | $86.6M | $90.4M | $89.9M | $85.5M | $86.2M |
| Long-term debt | $40.0M | $40.0M | $40.0M | $50.0M | $50.0M | $50.0M | $50.0M | $50.0M |
| Shareholders' equity | $27.9M | $20.9M | $11.1M | $1.14M | −$1.72M | −$2.46M | $9.13M | $9.14M |
| Cash flow | ||||||||
| Operating cash flow | −$10.7M | −$4.10M | −$8.60M | −$6.57M | −$8.88M | $778.0K | −$10.2M | −$1.56M |
| Capital expenditure | $231.0K | $839.0K | $74.0K | $51.0K | $48.0K | $86.0K | $81.0K | $197.0K |
| Free cash flow | −$10.9M | −$4.93M | −$8.68M | −$6.62M | −$8.93M | $692.0K | −$10.2M | −$1.76M |
From Biodesix's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Biodesix in our feed yet.